Divalproex for the treatment of posttraumatic stress disorder: A retrospective chart review

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 4, 2005, Pages 278-283

  Davis, Lori L ^a,b   Ambrose, Sandra M ^a   Newell, Jason M ^a   Waldrop, Elizabeth ^a   Cates, Marshall ^a,c   Ward, L Charles ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SAMFORD UNIVERSITY   (United States)

Author keywords

Anticonvulsant; Anxiety disorders; Divalproex; GABA; Posttraumatic stress disorder (PTSD); Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; LITHIUM; METHYLPHENIDATE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; CLINICAL ARTICLE; COMPUTER ANALYSIS; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MEDICAL RECORD; MENTAL HEALTH; MONOTHERAPY; POSTTRAUMATIC STRESS DISORDER; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SOLDIER; TREATMENT OUTCOME;

EID: 27844491555     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500500305564     Document Type: Review

References (34)

1. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995;52:1048-60.
2. Kulka RL, Schlenger WE, Fairbank JA, et al. The National Vietnam Veterans Readjustment Study: Tables of findings and technical appendices. New York: Brunner/Mazel Publishers; 1990.
3. Yehuda R, Orsillo SM, Weathers FW, et al. Current and lifetime psychiatric disorders among veterans with war zone-related PTSD. J Nerv Ment Dis 1996;184:307-13.
4. Davis LL, English BA, Ambrose SM, Petty F. Pharmacotherapy for posttraumatic stress disorder: A comprehensive review. Expert Opin Pharmacother 2001;2(10):1-13.
5. Schatzberg AF. New indications for antidepressants. J Clin Psych 2000;61(Suppl 11):9-17.
6. Baker DG, Diamond BL, Gillette G, et al. A double-blind, randomized, placebo-controlled, multicenter study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology 1995;122:386-9.
7. van der Kolk BA, Dreyfuss D, Michaels M, Shrea D, Berkowitz R, Fisler SG. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994;56:517-22.
8. Hertzsberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: A placebo controlled trial in combat veterans. Ann Clin Psychiatry 2000;12:101-5.
9. Davis LL, Jewell ME, Ambrose S, et al. Nefazodone for posttraumatic stress disorder: A placebo-controlled trial. J Clin Psychopharmacol 2004;24:291-7.
10. Post RM, Weiss SRB, Smith M, Li H, McCann U. Implications for the evolution and treatment of PTSD. In: Yehuda R, McFarlane AC, editors. Psychobiology of posttraumatic stress disorder. Ann NY Acad Sci 1997;821:285-95.
11. Berlant JL. Antiepileptic treatment of posttraumatic stress disorder. Primary Psychiatry 2003;10:1-10.
12. Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB. Divalproex in posttraumatic stress disorder: An open label clinical trial. J Traumatic Stress 1999;12:395-401.
13. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991;52:361.
14. Petty F, Davis LL, Nugent AL, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol 2002;22:100-1.
15. Goldberg JF, Whitney P, Whiteside JE, Cloitre M, Davis LL, Hyemee H. Divalproex in PTSD resulting from sexual abuse. Abstract. Washington, DC: American Psychiatric Association; 1999.
16. Otte C, Wiedemann K, Yassouridis A, Kellner M. Valproate monotherapy in the treatment of civilian patients with noncombat-related posttraumatic stress disorder: An open-label study. J Clin Psychopharmacol 2004;24:106-8.
17. Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986;27:849-54.
18. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans: Clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988;23:642-4.
19. Looff D, Grimley P, Kuller F, Martin A, Shonfield L. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 1995;34:703-4.
20. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J Clin Psychiatry 2002;1:15-20.
21. Berlant JL. Prospective open label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004;4:24.
22. Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder. Can J Psychiatry 2000;45:84.
23. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45:1226-9.
24. Berigan TR, Holzgang A. Valproate as an alternative in posttraumatic stress disorder: A case report. Military Med 1995;160:318.
25. Brodsky L, Doerman AL, Palmer LS, Slade GF, Munasifi FA. Posttraumatic stress disorder: an eclectic approach. Int J Psychosomat 1990;37:89-95.
26. Ford N. The use of anticonvulsants in posttraumatic stress disorder: Case study and overview. J Traumatic Stress 1996;9:857-63.
27. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry 1991;148:1086-7.
28. Loscher W. Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999;58:31-59.
29. Krystal J H, Bennett AL, Bremner JD, Southwick SM, Charney DS. Toward a cognitive neuroscience of dissociation and altered memory functions in post traumatic stress disorder. Philadelphia, PA: Lippincott-Raven; 1995.
30. Stutzmann GE, LeDoux JE. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: A mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci 1999;19(RC8):l-4.
31. Petty F, Kramer G, Wilson L. Prevention of learned helplessness: In vivo correlation with serotonin. Pharmacol Biochem Behav 1992;43:361-7.
32. Vaiva G, Thomas P, Ducrocq F, et al. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry 2004;55:250-4.
33. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
34. Krystal JH, Karper LP, Bennett A, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berlin) 1998;135:213-29.